source
- BMS reports phase 3 successes in IPF drug and neuroendocrine tumor radiotherapyBristol Myers Squibb announced that two of its phase 3 trials have met primary endpoints, marking important milestones as the company seeks growth beyond its patent expirations. The Aloft-IPF stud…
- Mirum's Livmarli cuts itching in ultra-rare liver disease trial, showing significant benefitMirum Pharmaceuticals reported that its ileal bile acid transporter inhibitor Livmarli achieved a statistically significant reduction in cholestatic pruritus compared with placebo in a late‑stage s…